Progress and problems with the use of suicide genes for targeted cancer therapy

Advanced Drug Delivery Reviews

Volumn 99, Issue , 2016, Pages 113-128

  Karjoo, Zahra ^a   Chen, Xuguang ^a   Hatefi, Arash ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Bystander effect; Cancer Gene therapy; Cytosine deaminase; Enzyme prodrug; Ganciclovir; GDEPT; Nitroreductase; Thymidine kinase

Indexed keywords

ANTIVIRAL AGENTS; BIOCHEMICAL ENGINEERING; CHEMICAL MODIFICATION; CHEMICAL STABILITY; DISEASES; ENZYMES; GENES;

BYSTANDER EFFECTS; CANCER GENE THERAPY; CYTOSINE DEAMINASE; GANCICLOVIR; GDEPT; NITROREDUCTASES; PRODRUGS; THYMIDINE KINASE;

GENE THERAPY;

2 HYDROXYLAMINE; 4 HYDROXYLAMINE; 6 METHYLPURINE; 6 METHYLPURINE DEOXYRIBOSIDE; ACROLEIN; ADENOVIRUS VECTOR; AMINOBENZOIC ACID DERIVATIVE; BEVACIZUMAB; BIS IODOPHENOL MUSTARD; CYCLOPHOSPHAMIDE; DIPHTHERIA TOXIN; DNA; DOXORUBICIN; DRUG METABOLITE; ENZYME; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; HYDROXYLAMINE; IFOSFAMIDE; IMATINIB; N [4 [(2 CHLOROETHYL)(2 MESYLOXYETHYL)AMINO]BENZOYL]GLUTAMIC ACID; N,N 2( CHLOROETHYL)(2 MESYLOXYETHYL)AMINOBENZOIC ACID; PHOSPHORAMIDE MUSTARD; PRODRUG; PURINE DERIVATIVE; THYMIDINE KINASE; TRETAZICAR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CELL; CANCER GENE THERAPY; CARDIOTOXICITY; CHEMICAL MODIFICATION; COLORECTAL CANCER; DERMATITIS; DIARRHEA; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME STABILITY; HEAD AND NECK CANCER; HUMAN; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; REVIEW; SOLID TUMOR; SUICIDE GENE THERAPY; THERAPEUTIC INDEX; TUMOR MICROENVIRONMENT; ANIMAL; GENE THERAPY; NEOPLASMS; SUICIDE TRANSGENE;

ANIMALS; ENZYMES; GENES, TRANSGENIC, SUICIDE; GENETIC THERAPY; HUMANS; NEOPLASMS; PRODRUGS;

EID: 84960285027     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.05.009     Document Type: Review

References (174)

1. Baban D.F., Seymour L.W. Control of tumour vascular permeability. Adv. Drug Deliv. Rev. 1998, 34:109-119.
2. Kobayashi H., Watanabe R., Choyke P.L. Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target?. Theranostics 2013, 4:81-89.
3. DeVita V.T., Chu E. A history of cancer chemotherapy. Cancer Res. 2008, 68:8643-8653.
4. Vandyke K., Fitter S., Dewar A.L., Hughes T.P., Zannettino A.C. Dysregulation of bone remodeling by imatinib mesylate. Blood 2010, 115:766-774.
5. Zhou Y., Kopecek J. Biological rationale for the design of polymeric anti-cancer nanomedicines. J. Drug Target. 2013, 21:1-26.
6. Barenholz Y. Doxil(R) - the first FDA-approved nano-drug: lessons learned. J. Control. Release 2012, 160:117-134.
7. Yao X.L., Yoshioka Y., Ruan G.X., Chen Y.Z., Mizuguchi H., Mukai Y., Okada N., Gao J.Q., Nakagawa S. Optimization and internalization mechanisms of PEGylated adenovirus vector with targeting peptide for cancer gene therapy. Biomacromolecules 2012, 13:2402-2409.
8. Yao X., Yoshioka Y., Morishige T., Eto Y., Watanabe H., Okada Y., Mizuguchi H., Mukai Y., Okada N., Nakagawa S. Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis. Gene Ther. 2009, 16:1395-1404.
9. Shah V., Taratula O., Garbuzenko O.B., Taratula O.R., Rodriguez-Rodriguez L., Minko T. Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug. Clin. Cancer Res. 2013, 19:6193-6204.
10. Liu J., Zhang C., Hu W., Feng Z. Tumor suppressor p53 and its mutants in cancer metabolism. Cancer Lett. 2015, 356:197-203.
11. Senzer N., Nemunaitis J., Nemunaitis D., Bedell C., Edelman G., Barve M., Nunan R., Pirollo K.F., Rait A., Chang E.H. Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol. Ther. 2013, 21:1096-1103.
12. Tabernero J., Shapiro G.I., LoRusso P.M., Cervantes A., Schwartz G.K., Weiss G.J., Paz-Ares L., Cho D.C., Infante J.R., Alsina M., Gounder M.M., Falzone R., Harrop J., White A.C., Toudjarska I., Bumcrot D., Meyers R.E., Hinkle G., Svrzikapa N., Hutabarat R.M., Clausen V.A., Cehelsky J., Nochur S.V., Gamba-Vitalo C., Vaishnaw A.K., Sah D.W., Gollob J.A., Burris H.A. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013, 3:406-417.
13. Chen Y., Gao D.Y., Huang L. In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Adv. Drug Deliv. Rev. 2015, 81:128-141.
14. van der Meel R., Vehmeijer L.J., Kok R.J., Storm G., van Gaal E.V. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Adv. Drug Deliv. Rev. 2013, 65:1284-1298.
15. Portsmouth D., Hlavaty J., Renner M. Suicide genes for cancer therapy. Mol. Asp. Med. 2007, 28:4-41.
16. Dorer D.E., Nettelbeck D.M. Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv. Drug Deliv. Rev. 2009, 61:554-571.
17. Yao X.L., Nakagawa S., Gao J.Q. Current targeting strategies for adenovirus vectors in cancer gene therapy. Curr. Cancer Drug Targets 2011, 11:810-825.
18. Xu Y., Hou J., Liu Z., Yu H., Sun W., Xiong J., Liao Z., Zhou F., Xie C., Zhou Y. Gene therapy with tumor-specific promoter mediated suicide gene plus IL-12 gene enhanced tumor inhibition and prolonged host survival in a murine model of Lewis lung carcinoma. J. Transl. Med. 2011, 9:39.
19. Dabrowska A., Szary J., Kowalczuk M., Szala S., Ugorski M. CEA-negative glioblastoma and melanoma cells are sensitive to cytosine deaminase/5-fluorocytosine therapy directed by the carcinoembryonic antigen promoter. Acta Biochim. Pol. 2004, 51:723-732.
20. Greco O., Marples B., Joiner M.C., Scott S.D. How to overcome (and exploit) tumor hypoxia for targeted gene therapy. J. Cell. Physiol. 2003, 197:312-325.
21. Scott S.D., Greco O. Radiation and hypoxia inducible gene therapy systems. Cancer Metastasis Rev. 2004, 23:269-276.
22. Robson T., Hirst D.G. Transcriptional targeting in cancer gene therapy. J. Biomed. Biotechnol. 2003, 2003:110-137.
23. Papadakis E.D., Nicklin S.A., Baker A.H., White S.J. Promoters and control elements: designing expression cassettes for gene therapy. Curr. Gene Ther. 2004, 4:89-113.
24. Karjoo Z., Ganapathy V., Hatefi A. Gene directed enzyme prodrug cancer therapy. Gene Therapy of Cancer, Translational Approaches from Preclinical Studies to Clinical Implemantation 2013, 77-91. Elsevier. E.S. Lattime, S. Gerson (Eds.).
25. Nemunaitis J., Tong A.W., Nemunaitis M., Senzer N., Phadke A.P., Bedell C., Adams N., Zhang Y.A., Maples P.B., Chen S., Pappen B., Burke J., Ichimaru D., Urata Y., Fujiwara T. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol. Ther. 2010, 18:429-434.
26. Wu L., Matherly J., Smallwood A., Adams J.Y., Billick E., Belldegrun A., Carey M. Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors. Gene Ther. 2001, 8:1416-1426.
27. Kanegae Y., Terashima M., Kondo S., Fukuda H., Maekawa A., Pei Z., Saito I. High-level expression by tissue/cancer-specific promoter with strict specificity using a single-adenoviral vector. Nucleic Acids Res. 2011, 39:e7.
28. Chen X.G., Godbey W.T. The potential of the human osteopontin promoter and single-nucleotide polymorphisms for targeted cancer gene therapy. Curr. Gene Ther. 2015, 15:82-92.
29. Chuah M.K., Petrus I., De Bleser P., Le Guiner C., Gernoux G., Adjali O., Nair N., Willems J., Evens H., Rincon M.Y., Matrai J., Di Matteo M., Samara-Kuko E., Yan B., Acosta-Sanchez A., Meliani A., Cherel G., Blouin V., Christophe O., Moullier P., Mingozzi F., VandenDriessche T. Liver-specific transcriptional modules identified by genome-wide in silico analysis enable efficient gene therapy in mice and non-human primates. Mol. Ther. 2014, 22:1605-1613.
30. Huber B.E., Austin E.A., Richards C.A., Davis S.T., Good S.S. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:8302-8306.
31. Ardiani A., Johnson A.J., Ruan H., Sanchez-Bonilla M., Serve K., Black M.E. Enzymes to die for: exploiting nucleotide metabolizing enzymes for cancer gene therapy. Curr. Gene Ther. 2012, 12:77-91.
32. Xiao J., Zhang G., Qiu P., Liu X., Wu Y., Du B., Li J., Zhou J., Tan Y. Tanshinone IIA increases the bystander effect of herpes simplex virus thymidine kinase/ganciclovir gene therapy via enhanced gap junctional intercellular communication. PLoS One 2013, 8:e67662.
33. Freeman S.M., Abboud C.N., Whartenby K.A., Packman C.H., Koeplin D.S., Moolten F.L., Abraham G.N. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993, 53:5274-5283.
34. Engelmann C., Heslan J.-M., Fabre M., Lagarde J.-P., Klatzmann D., Panis Y. Importance, mechanisms and limitations of the distant bystander effect in cancer gene therapy of experimental liver tumors. Cancer Lett. 2002, 179:59-69.
35. Kuriyama S., Tsujinoue H., Yoshiji H. Immune response to suicide gene therapy. Methods Mol. Med. 2004, 90:353-369.
36. Pierrefite-Carle V., Baque P., Gavelli A., Brossette N., Benchimol D., Bourgeon A., Saint Paul M.C., Staccini P., Rossi B. Subcutaneous or intrahepatic injection of suicide gene modified tumour cells induces a systemic antitumour response in a metastatic model of colon carcinoma in rats. Gut 2002, 50:387-391.
37. Aguilar L.K., Guzik B.W., Aguilar-Cordova E. Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development. J. Cell. Biochem. 2011, 112:1969-1977.
38. Agard C., Ligeza C., Dupas B., Izembart A., El Kouri C., Moullier P., Ferry N. Immune-dependent distant bystander effect after adenovirus-mediated suicide gene transfer in a rat model of liver colorectal metastasis. Cancer Gene Ther. 2001, 8:128-136.
39. Niculescu-Duvaz I., Springer C.J. Introduction to the background, principles, and state of the art in suicide gene therapy. Mol. Biotechnol. 2005, 30:71-88.
40. Yoon K.J., Potter P.M., Danks M.K. Development of prodrugs for enzyme-mediated, tumor-selective therapy. Curr. Med. Chem. Anticancer Agents 2005, 5:107-113.
41. Niculescu-Duvaz D., Niculescu-Duvaz I., Springer C.J. Design of prodrugs for suicide gene therapy. Methods Mol. Med. 2004, 90:161-202.
42. Niculescu-Duvaz I., Niculescu-Duvaz D., Friedlos F., Spooner R., Martin J., Marais R., Springer C.J. Self-immolative anthracycline prodrugs for suicide gene therapy. J. Med. Chem. 1999, 42:2485-2489.
43. Tranoy-Opalinski I., Legigan T., Barat R., Clarhaut J., Thomas M., Renoux B., Papot S. Beta-glucuronidase-responsive prodrugs for selective cancer chemotherapy: An update. Eur. J. Med. Chem. 2014, 74:302-313.
44. Tranoy-Opalinski I., Fernandes A., Thomas M., Gesson J.P., Papot S. Design of self-immolative linkers for tumour-activated prodrug therapy. Anti Cancer Agents Med. Chem. 2008, 8:618-637.
45. Lammers T., Kiessling F., Hennink W.E., Storm G. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J. Control. Release 2012, 161:175-187.
46. Halama A., Kulinski M., Librowski T., Lochynski S. Polymer-based non-viral gene delivery as a concept for the treatment of cancer. Pharmacol. Rep. 2009, 61:993-999.
47. McCarthy H.O., Wang Y., Mangipudi S.S., Hatefi A. Advances with the use of bio-inspired vectors towards creation of artificial viruses. Expert Opin. Drug Deliv. 2010, 7:497-512.
48. Mohit E., Rafati S. Biological delivery approaches for gene therapy: strategies to potentiate efficacy and enhance specificity. Mol. Immunol. 2013, 56:599-611.
49. Ginn S.L., Alexander I.E., Edelstein M.L., Abedi M.R., Wixon J. Gene therapy clinical trials worldwide to 2012 - an update. J. Gene Med. 2013, 15:65-77.
50. Beatty M.S., Curiel D.T. Chapter two - adenovirus strategies for tissue-specific targeting. Adv. Cancer Res. 2012, 115:39-67.
51. Shen Y., Nemunaitis J. Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther. 2006, 13:975-992.
52. Thomas C.E., Ehrhardt A., Kay M.A. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 2003, 4:346-358.
53. Penet M.F., Chen Z., Li C., Winnard P.T., Bhujwalla Z.M. Prodrug enzymes and their applications in image-guided therapy of cancer: tracking prodrug enzymes to minimize collateral damage. J. Gene Med. 2012, 2:22-30.
54. Wilcox C.L., Crnic L.S., Pizer L.I. Replication, latent infection, and reactivation in neuronal culture with a herpes simplex virus thymidine kinase-negative mutant. Virology 1992, 187:348-352.
55. Chen S.H., Pearson A., Coen D.M. Failure of thymidine kinase-negative herpes simplex virus to reactivate from latency following efficient establishment. J. Virol. 2004, 78:520-523.
56. Piret J., Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob. Agents Chemother. 2011, 55:459-472.
57. Gallois-Montbrun S., Veron M., Deville-Bonne D. Antiviral nucleoside analogs phosphorylation by nucleoside diphosphate kinase. Mini Rev. Med. Chem. 2004, 4:361-369.
58. Beltinger C., Fulda S., Kammertoens T., Meyer E., Uckert W., Debatin K.M. Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:8699-8704.
59. Nicholas T.W., Read S.B., Burrows F.J., Kruse C.A. Suicide gene therapy with Herpes simplex virus thymidine kinase and ganciclovir is enhanced with connexins to improve gap junctions and bystander effects. Histol. Histopathol. 2003, 18:495-507.
60. Preuss E., Muik A., Weber K., Otte J., von Laer D., Fehse B. Cancer suicide gene therapy with TK.007: superior killing efficiency and bystander effect. J. Mol. Med. 2011, 89:1113-1124.
61. Mesnil M., Yamasaki H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res. 2000, 60:3989-3999.
62. Dachs G., Hunt M., Syddall S., Singleton D., Patterson A. Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules 2009, 14:4517-4545.
63. Black M.E., Kokoris M.S., Sabo P. Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res. 2001, 61:3022-3026.
64. Ardiani A., Sanchez-Bonilla M., Black M.E. Fusion enzymes containing HSV-1 thymidine kinase mutants and guanylate kinase enhance prodrug sensitivity in vitro and in vivo. Cancer Gene Ther. 2010, 17:86-96.
65. Balzarini J., Liekens S., Solaroli N., El Omari K., Stammers D.K., Karlsson A. Engineering of a single conserved amino acid residue of herpes simplex virus type 1 thymidine kinase allows a predominant shift from pyrimidine to purine nucleoside phosphorylation. J. Biol. Chem. 2006, 281:19273-19279.
66. Blumenthal M., Skelton D., Pepper K.A., Jahn T., Methangkool E., Kohn D.B. Effective suicide gene therapy for leukemia in a model of insertional oncogenesis in mice. Mol. Ther. 2007, 15:183-192.
67. Barzon L., Pacenti M., Franchin E., Colombo F., Palu G. HSV-TK/IL-2 gene therapy for glioblastoma multiforme. Methods Mol. Biol. 2009, 542:529-549.
68. Pan J.G., Zhou X., Luo R., Han R.F. The adeno-associated virus-mediated HSV-TK/GCV suicide system: a potential strategy for the treatment of bladder carcinoma. Med. Oncol. 2012, 29:1938-1947.
69. Wang Y., Canine B.F., Hatefi A. HSV-TK/GCV cancer suicide gene therapy by a designed recombinant multifunctional vector. Nanomedicine 2011, 7:193-200.
70. Voges J., Reszka R., Gossmann A., Dittmar C., Richter R., Garlip G., Kracht L., Coenen H.H., Sturm V., Wienhard K., Heiss W.D., Jacobs A.H. Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma. Ann. Neurol. 2003, 54:479-487.
71. Nasu Y., Saika T., Ebara S., Kusaka N., Kaku H., Abarzua F., Manabe D., Thompson T.C., Kumon H. Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy. Mol. Ther. 2007, 15:834-840.
72. Li N., Zhou J., Weng D., Zhang C., Li L., Wang B., Song Y., He Q., Lin D., Chen D., Chen G., Gao Q., Wang S., Xu G., Meng L., Lu Y., Ma D. Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 2007, 13:5847-5854.
73. Xu F., Li S., Li X.L., Guo Y., Zou B.Y., Xu R., Liao H., Zhao H.Y., Zhang Y., Guan Z.Z., Zhang L. Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors. Cancer Gene Ther. 2009, 16:723-730.
74. Sangro B., Mazzolini G., Ruiz M., Ruiz J., Quiroga J., Herrero I., Qian C., Benito A., Larrache J., Olague C., Boan J., Penuelas I., Sadaba B., Prieto J. A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma. Cancer Gene Ther. 2010, 17:837-843.
75. Langford G., Dayan A., Yla-Herttuala S., Eckland D. A preclinical assessment of the safety and biodistribution of an adenoviral vector containing the herpes simplex virus thymidine kinase gene (Cerepro) after intracerebral administration. J. Gene Med. 2009, 11:468-476.
76. van Putten E.H., Dirven C.M., van den Bent M.J., Lamfers M.L. Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma. Future Oncol. 2010, 6:1691-1710.
77. Matthews K., Noker P.E., Tian B., Grimes S.D., Fulton R., Schweikart K., Harris R., Aurigemma R., Wang M., Barnes M.N., Siegal G.P., Hemminki A., Zinn K., Curiel D.T., Alvarez R.D. Identifying the safety profile of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in anticipation of a phase I clinical trial in patients with recurrent ovarian cancer. Clin. Cancer Res. 2009, 15:4131-4137.
78. Witlox M.A., Van Beusechem V.W., Grill J., Haisma H.J., Schaap G., Bras J., Van Diest P., De Gast A., Curiel D.T., Pinedo H.M., Gerritsen W.R., Wuisman P.I. Epidermal growth factor receptor targeting enhances adenoviral vector based suicide gene therapy of osteosarcoma. J. Gene Med. 2002, 4:510-516.
79. Nicklin S.A., Baker A.H. Tropism-modified adenoviral and adeno-associated viral vectors for gene therapy. Curr. Gene Ther. 2002, 2:273-293.
80. Verheije M.H., Rottier P.J. Retargeting of viruses to generate oncolytic agents. Adv. Virol. 2012, 2012:798526.
81. Kim K.H., Dmitriev I., O'Malley J.P., Wang M., Saddekni S., You Z., Preuss M.A., Harris R.D., Aurigemma R., Siegal G.P., Zinn K.R., Curiel D.T., Alvarez R.D. A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer. Clin. Cancer Res. 2012, 18:3440-3451.
82. Kubo H., Gardner T.A., Wada Y., Koeneman K.S., Gotoh A., Yang L., Kao C., Lim S.D., Amin M.B., Yang H., Black M.E., Matsubara S., Nakagawa M., Gillenwater J.Y., Zhau H.E., Chung L.W. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum. Gene Ther. 2003, 14:227-241.
83. Papanastasopoulos P., Stebbing J. Molecular basis of 5-fluorouracil-related toxicity: lessons from clinical practice. Anticancer Res. 2014, 34:1531-1535.
84. Miller C.R., Williams C.R., Buchsbaum D.J., Gillespie G.Y. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res. 2002, 62:773-780.
85. Kuriyama S., Masui K., Sakamoto T., Nakatani T., Kikukawa M., Tsujinoue H., Mitoro A., Yamazaki M., Yoshiji H., Fukui H., Ikenaka K., Mullen C.A., Tsujii T. Bystander effect caused by cytosine deaminase gene and 5-fluorocytosine in vitro is substantially mediated by generated 5-fluorouracil. Anticancer Res. 1998, 18:3399-3406.
86. Garcia-Sanchez F., Pizzorno G., Fu S.Q., Nanakorn T., Krause D.S., Liang J., Adams E., Leffert J.J., Yin L.H., Cooperberg M.R., Hanania E., Wang W.L., Won J.H., Peng X.Y., Cote R., Brown R., Burtness B., Giles R., Crystal R., Deisseroth A.B. Cytosine deaminase adenoviral vector and 5-fluorocytosine selectively reduce breast cancer cells 1 million-fold when they contaminate hematopoietic cells: a potential purging method for autologous transplantation. Blood 1998, 92:672-682.
87. Ostertag D., Amundson K.K., Lopez Espinoza F., Martin B., Buckley T., Galvao da Silva A.P., Lin A.H., Valenta D.T., Perez O.D., Ibanez C.E., Chen C.I., Pettersson P.L., Burnett R., Daublebsky V., Hlavaty J., Gunzburg W., Kasahara N., Gruber H.E., Jolly D.J., Robbins J.M. Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. J. Neuro Oncol. 2012, 14:145-159.
88. Kaliberov S.A., Buchsbaum D.J. Chapter seven - cancer treatment with gene therapy and radiation therapy. Adv. Cancer Res. 2012, 115:221-263.
89. Tong X., Chen X., Li C. Imaging beyond the diagnosis: image-guided enzyme/prodrug cancer therapy. Acta Biochim. Biophys. Sin. 2011, 43:4-12.
90. Haack K., Linnebacher M., Eisold S., Zoller M., von Knebel Doeberitz M., Gebert J. Induction of protective immunity against syngeneic rat cancer cells by expression of the cytosine deaminase suicide gene. Cancer Gene Ther. 2000, 7:1357-1364.
91. Kaliberova L.N., Della Manna D.L., Krendelchtchikova V., Black M.E., Buchsbaum D.J., Kaliberov S.A. Molecular chemotherapy of pancreatic cancer using novel mutant bacterial cytosine deaminase gene. Mol. Cancer Ther. 2008, 7:2845-2854.
92. Deng L.Y., Wang J.P., Gui Z.F., Shen L.Z. Antitumor activity of mutant bacterial cytosine deaminase gene for colon cancer. World J. Gastroenterol. 2011, 17:2958-2964.
93. Fuchita M., Ardiani A., Zhao L., Serve K., Stoddard B.L., Black M.E. Bacterial cytosine deaminase mutants created by molecular engineering show improved 5-fluorocytosine-mediated cell killing in vitro and in vivo. Cancer Res. 2009, 69:4791-4799.
94. Stolworthy T.S., Korkegian A.M., Willmon C.L., Ardiani A., Cundiff J., Stoddard B.L., Black M.E. Yeast cytosine deaminase mutants with increased thermostability impart sensitivity to 5-fluorocytosine. J. Mol. Biol. 2008, 377:854-869.
95. Korkegian A., Black M.E., Baker D., Stoddard B.L. Computational thermostabilization of an enzyme. Science 2005, 308:857-860.
96. Shi D.Z., Hu W.X., Li L.X., Chen G., Wei D., Gu P.Y. Pharmacokinetics and the bystander effect in CD::UPRT/5-FC bi-gene therapy of glioma. Chin. Med. J. 2009, 122:1267-1272.
97. Richard C., Duivenvoorden W., Bourbeau D., Massie B., Roa W., Yau J., Th'ng J. Sensitivity of 5-fluorouracil-resistant cancer cells to adenovirus suicide gene therapy. Cancer Gene Ther. 2007, 14:57-65.
98. Freytag S.O., Khil M., Stricker H., Peabody J., Menon M., DePeralta-Venturina M., Nafziger D., Pegg J., Paielli D., Brown S., Barton K., Lu M., Aguilar-Cordova E., Kim J.H. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 2002, 62:4968-4976.
99. Freytag S.O., Barton K.N., Brown S.L., Narra V., Zhang Y., Tyson D., Nall C., Lu M., Ajlouni M., Movsas B., Kim J.H. Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer. Mol. Ther. 2007, 15:1600-1606.
100. Freytag S.O., Stricker H., Pegg J., Paielli D., Pradhan D.G., Peabody J., DePeralta-Venturina M., Xia X., Brown S., Lu M., Kim J.H. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res. 2003, 63:7497-7506.
101. Freytag S.O., Movsas B., Aref I., Stricker H., Peabody J., Pegg J., Zhang Y., Barton K.N., Brown S.L., Lu M., Savera A., Kim J.H. Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol. Ther. 2007, 15:1016-1023.
102. Freytag S.O., Stricker H., Peabody J., Pegg J., Paielli D., Movsas B., Barton K.N., Brown S.L., Lu M., Kim J.H. Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol. Ther. 2007, 15:636-642.
103. Perez O.D., Logg C.R., Hiraoka K., Diago O., Burnett R., Inagaki A., Jolson D., Amundson K., Buckley T., Lohse D., Lin A., Burrascano C., Ibanez C., Kasahara N., Gruber H.E., Jolly D.J. Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression. Mol. Ther. 2012, 20:1689-1698.
104. Stedt H., Samaranayake H., Pikkarainen J., Maatta A.M., Alasaarela L., Airenne K., Yla-Herttuala S. Improved therapeutic effect on malignant glioma with adenoviral suicide gene therapy combined with temozolomide. Gene Ther. 2013, 20:1165-1171.
105. Greco O., Dachs G.U. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J. Cell. Physiol. 2001, 187:22-36.
106. Green L.K., Storey M.A., Williams E.M., Patterson A.V., Smaill J.B., Copp J.N., Ackerley D.F. The flavin reductase MsuE is a novel nitroreductase that can efficiently activate two promising next-generation prodrugs for gene-directed enzyme prodrug therapy. Cancers (Basel) 2013, 5:985-997.
107. Chung-Faye G., Palmer D., Anderson D., Clark J., Downes M., Baddeley J., Hussain S., Murray P.I., Searle P., Seymour L., Harris P.A., Ferry D., Kerr D.J. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clin. Cancer Res. 2001, 7:2662-2668.
108. Prosser G.A., Copp J.N., Syddall S.P., Williams E.M., Smaill J.B., Wilson W.R., Patterson A.V., Ackerley D.F. Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954. Biochem. Pharmacol. 2010, 79:678-687.
109. Grohmann M., Paulmann N., Fleischhauer S., Vowinckel J., Priller J., Walther D.J. A mammalianized synthetic nitroreductase gene for high-level expression. BMC Cancer 2009, 9:301.
110. Prosser G.A., Copp J.N., Mowday A.M., Guise C.P., Syddall S.P., Williams E.M., Horvat C.N., Swe P.M., Ashoorzadeh A., Denny W.A., Smaill J.B., Patterson A.V., Ackerley D.F. Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A. Biochem. Pharmacol. 2013, 85:1091-1103.
111. Swe P.M., Copp J.N., Green L.K., Guise C.P., Mowday A.M., Smaill J.B., Patterson A.V., Ackerley D.F. Targeted mutagenesis of the Vibrio fischeri flavin reductase FRase I to improve activation of the anticancer prodrug CB1954. Biochem. Pharmacol. 2012, 84:775-783.
112. Green L.K., Syddall S.P., Carlin K.M., Bell G.D., Guise C.P., Mowday A.M., Hay M.P., Smaill J.B., Patterson A.V., Ackerley D.F. Pseudomonas aeruginosa NfsB and nitro-CBI-DEI - a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy. Mol. Cancer 2013, 12:58.
113. Patel P., Young J.G., Mautner V., Ashdown D., Bonney S., Pineda R.G., Collins S.I., Searle P.F., Hull D., Peers E., Chester J., Wallace D.M., Doherty A., Leung H., Young L.S., James N.D. A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984]. Mol. Ther. 2009, 17:1292-1299.
114. Barar J., Omidi Y. Translational approaches towards cancer gene therapy: hurdles and hopes. Biogeosciences 2012, 2:127-143.
115. Nouri F.S., Wang X., Hatefi A. Genetically engineered theranostic mesenchymal stem cells for the evaluation of the anticancer efficacy of enzyme/prodrug systems. J. Control. Release 2015, 200:179-187.
116. Guise C.P., Abbattista M.R., Singleton R.S., Holford S.D., Connolly J., Dachs G.U., Fox S.B., Pollock R., Harvey J., Guilford P., Donate F., Wilson W.R., Patterson A.V. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. Cancer Res. 2010, 70:1573-1584.
117. Hedley D., Ogilvie L., Springer C. Carboxypeptidase-G2-based gene-directed enzyme-prodrug therapy: a new weapon in the GDEPT armoury. Nat. Rev. Cancer 2007, 7:870-879.
118. Palmer D.H., Mautner V., Mirza D., Oliff S., Gerritsen W., van der Sijp J.R., Hubscher S., Reynolds G., Bonney S., Rajaratnam R., Hull D., Horne M., Ellis J., Mountain A., Hill S., Harris P.A., Searle P.F., Young L.S., James N.D., Kerr D.J. Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J. Clin. Oncol. 2004, 22:1546-1552.
119. Stribbling S.M., Friedlos F., Martin J., Davies L., Spooner R.A., Marais R., Springer C.J. Regressions of established breast carcinoma xenografts by carboxypeptidase G2 suicide gene therapy and the prodrug CMDA are due to a bystander effect. Hum. Gene Ther. 2000, 11:285-292.
120. Francis R.J., Sharma S.K., Springer C., Green A.J., Hope-Stone L.D., Sena L., Martin J., Adamson K.L., Robbins A., Gumbrell L., O'Malley D., Tsiompanou E., Shahbakhti H., Webley S., Hochhauser D., Hilson A.J., Blakey D., Begent R.H. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br. J. Cancer 2002, 87:600-607.
121. Friedlos F., Davies L., Scanlon I., Ogilvie L.M., Martin J., Stribbling S.M., Spooner R.A., Niculescu-Duvaz I., Marais R., Springer C.J. Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models. Cancer Res. 2002, 62:1724-1729.
122. Mancini L., Davies L., Friedlos F., Falck-Miniotis M., Dzik-Jurasz A.S., Springer C.J., Leach M.O., Payne G.S. A novel technique to monitor carboxypeptidase G2 expression in suicide gene therapy using 19 F magnetic resonance spectroscopy. NMR Biomed. 2009, 22:561-566.
123. Mahato R., Tai W., Cheng K. Prodrugs for improving tumor targetability and efficiency. Adv. Drug Deliv. Rev. 2011, 63:659-670.
124. Martin J., Stribbling S.M., Poon G.K., Begent R.H., Napier M., Sharma S.K., Springer C.J. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial. Cancer Chemother. Pharmacol. 1997, 40:189-201.
125. Chiocca E.A., Waxman D.J. Cytochrome p450-based gene therapies for cancer. Methods Mol. Med. 2004, 90:203-222.
126. Huang Z., Waxman D.J. Modulation of cyclophosphamide-based cytochrome P450 gene therapy using liver P450 inhibitors. Cancer Gene Ther. 2001, 8:450-458.
127. Chen L., Waxman D.J. Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr. Pharm. Des. 2002, 8:1405-1416.
128. Salmons B., Lohr M., Gunzburg W.H. Treatment of inoperable pancreatic carcinoma using a cell-based local chemotherapy: results of a phase I/II clinical trial. J. Gastroenterol. 2003, 38(Suppl. 15):78-84.
129. Braybrooke J.P., Slade A., Deplanque G., Harrop R., Madhusudan S., Forster M.D., Gibson R., Makris A., Talbot D.C., Steiner J., White L., Kan O., Naylor S., Carroll M.W., Kingsman S.M., Harris A.L. Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma. Clin. Cancer Res. 2005, 11:1512-1520.
130. Touati W., Tran T., Seguin J., Diry M., Flinois J.P., Baillou C., Lescaille G., Andre F., Tartour E., Lemoine F.M., Beaune P., de Waziers I. A suicide gene therapy combining the improvement of cyclophosphamide tumor cytotoxicity and the development of an anti-tumor immune response. Curr. Gene Ther. 2014, 14:236-246.
131. Gadi V.K., Alexander S.D., Waud W.R., Allan P.W., Parker W.B., Sorscher E.J. A long-acting suicide gene toxin, 6-methylpurine, inhibits slow growing tumors after a single administration. J. Pharmacol. Exp. Ther. 2003, 304:1280-1284.
132. Hong J.S., Waud W.R., Levasseur D.N., Townes T.M., Wen H., McPherson S.A., Moore B.A., Bebok Z., Allan P.W., Secrist J.A., Parker W.B., Sorscher E.J. Excellent in vivo bystander activity of fludarabine phosphate against human glioma xenografts that express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res. 2004, 64:6610-6615.
133. Martiniello-Wilks R., Garcia-Aragon J., Daja M.M., Russell P., Both G.W., Molloy P.L., Lockett L.J., Russell P.J. In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. Hum. Gene Ther. 1998, 9:1617-1626.
134. Lockett L.J., Molloy P.L., Russell P.J., Both G.W. Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors. Clin. Cancer Res. 1997, 3:2075-2080.
135. Afshar S., Asai T., Morrison S.L. Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer. Mol. Cancer Ther. 2009, 8:185-193.
136. Voeks D., Martiniello-Wilks R., Madden V., Smith K., Bennetts E., Both G.W., Russell P.J. Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models. Gene Ther. 2002, 9:759-768.
137. Parker W.B., Allan P.W., Waud W.R., Hong J.S., Sorscher E.J. Effect of expression of adenine phosphoribosyltransferase on the in vivo anti-tumor activity of prodrugs activated by E. coli purine nucleoside phosphorylase. Cancer Gene Ther. 2011, 18:390-398.
138. Bennett E.M., Anand R., Allan P.W., Hassan A.E., Hong J.S., Levasseur D.N., McPherson D.T., Parker W.B., Secrist J.A., Sorscher E.J., Townes T.M., Waud W.R., Ealick S.E. Designer gene therapy using an Escherichia coli purine nucleoside phosphorylase/prodrug system. Chem. Biol. 2003, 10:1173-1181.
139. Parker W.B., Allan P.W., Ealick S.E., Sorscher E.J., Hassan A.E., Silamkoti A.V., Fowler A.T., Waud W.R., Secrist J.A. Design and evaluation of 5'-modified nucleoside analogs as prodrugs for an E. coli purine nucleoside phosphorylase mutant. Nucleosides Nucleotides Nucleic Acids 2005, 24:387-392.
140. Xie X., Guo J., Kong Y., Xie G.X., Li L., Lv N., Xiao X., Tang J., Wang X., Liu P., Yang M., Xie Z., Wei W., Spencer D.M., Xie X. Targeted expression of Escherichia coli purine nucleoside phosphorylase and Fludara(R) for prostate cancer therapy. J. Gene Med. 2011, 13:680-691.
141. Chen Z.H., Huang G.L., Tu Y.Q., Jiang Y., Dai W.X. Dual specific antitumor effects of Semliki Forest virus-based DNA vector carrying suicide Escherichia coli purine nucleoside phosphorylase gene via Salmonella. Int. J. Oncol. 2013, 42:2009-2018.
142. Sorscher E.J., Hong J.S., Allan P.W., Waud W.R., Parker W.B. In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing E. coli purine nucleoside phosphorylase. Cancer Chemother. Pharmacol. 2012, 70:321-329.
143. Greco O., Rossiter S., Kanthou C., Folkes L.K., Wardman P., Tozer G.M., Dachs G.U. Horseradish peroxidase-mediated gene therapy: choice of prodrugs in oxic and anoxic tumor conditions. Mol. Cancer Ther. 2001, 1:151-160.
144. Greco O., Tozer G.M., Dachs G.U. Oxic and anoxic enhancement of radiation-mediated toxicity by horseradish peroxidase/indole-3-acetic acid gene therapy. Int. J. Radiat. Biol. 2002, 78:173-181.
145. Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 2006, 6:789-802.
146. Metz M.Z., Gutova M., Lacey S.F., Abramyants Y., Vo T., Gilchrist M., Tirughana R., Ghoda L.Y., Barish M.E., Brown C.E., Najbauer J., Potter P.M., Portnow J., Synold T.W., Aboody K.S. Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use. Stem cells Transl. Med. 2013, 2:983-992.
147. Mathijssen R.H., van Alphen R.J., Verweij J., Loos W.J., Nooter K., Stoter G., Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res. 2001, 7:2182-2194.
148. Swami U., Goel S., Mani S. Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis. Curr. Drug Targets 2013, 14:777-797.
149. Chiocca E.A., Aguilar L.K., Bell S.D., Kaur B., Hardcastle J., Cavaliere R., McGregor J., Lo S., Ray-Chaudhuri A., Chakravarti A., Grecula J., Newton H., Harris K.S., Grossman R.G., Trask T.W., Baskin D.S., Monterroso C., Manzanera A.G., Aguilar-Cordova E., New P.Z. Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. J. Clin. Oncol. 2011, 29:3611-3619.
150. Finocchiaro L.M., Glikin G.C. Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma: 9 years of follow-up. Cancer Gene Ther. 2012, 19:852-861.
151. Xiong J., Sun W.J., Wang W.F., Liao Z.K., Zhou F.X., Kong H.Y., Xu Y., Xie C.H., Zhou Y.F. Novel, chimeric, cancer-specific, and radiation-inducible gene promoters for suicide gene therapy of cancer. Cancer 2012, 118:536-548.
152. Liao Z., Huang C., Zhou F., Xiong J., Bao J., Zhang H., Sun W., Xie C., Zhou Y. Radiation enhances suicide gene therapy in radioresistant laryngeal squamous cell carcinoma via activation of a tumor-specific promoter. Cancer Lett. 2009, 283:20-28.
153. Louis C.U., Savoldo B., Dotti G., Pule M., Yvon E., Myers G.D., Rossig C., Russell H.V., Diouf O., Liu E., Liu H., Wu M.F., Gee A.P., Mei Z., Rooney C.M., Heslop H.E., Brenner M.K. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011, 118:6050-6056.
154. Kalos M., Levine B.L., Porter D.L., Katz S., Grupp S.A., Bagg A., June C.H. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 2011, 3:95ra73.
155. Zhong X.S., Matsushita M., Plotkin J., Riviere I., Sadelain M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol. Ther. 2010, 18:413-420.
156. Grupp S.A., Kalos M., Barrett D., Aplenc R., Porter D.L., Rheingold S.R., Teachey D.T., Chew A., Hauck B., Wright J.F., Milone M.C., Levine B.L., June C.H. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 2013, 368:1509-1518.
157. Tey S.K. Adoptive T-cell therapy: adverse events and safety switches. Clin. Transl. Immunol. 2014, 3:e17.
158. Mailly L., Leboeuf C., Tiberghien P., Baumert T., Robinet E. Genetically engineered T-cells expressing a ganciclovir-sensitive HSV-tk suicide gene for the prevention of GvHD. Curr. Opin. Investig. Drugs 2010, 11:559-570.
159. Faneca H., Faustino A., Pedroso de Lima M.C. Synergistic antitumoral effect of vinblastine and HSV-Tk/GCV gene therapy mediated by albumin-associated cationic liposomes. J. Control. Release 2008, 126:175-184.
160. Boucher P.D., Shewach D.S. In vitro and in vivo enhancement of ganciclovir-mediated bystander cytotoxicity with gemcitabine. Mol. Ther. 2005, 12:1064-1071.
161. Zhang H. Multifunctional nanomedicine platforms for cancer therapy. J. Nanosci. Nanotechnol. 2012, 12:4012-4018.
162. Duarte S., Carle G., Faneca H., de Lima M.C., Pierrefite-Carle V. Suicide gene therapy in cancer: where do we stand now?. Cancer Lett. 2012, 324:160-170.
163. Kurayoshi K., Ozono E., Iwanaga R., Bradford A.P., Komori H., Ohtani K. Cancer cell specific cytotoxic gene expression mediated by ARF tumor suppressor promoter constructs. Biochem. Biophys. Res. Commun. 2014, 450:240-246.
164. Leja J., Dzojic H., Gustafson E., Oberg K., Giandomenico V., Essand M. A novel chromogranin - a promoter-driven oncolytic adenovirus for midgut carcinoid therapy. Clin. Cancer Res. 2007, 13:2455-2462.
165. Kia A., Przystal J.M., Nianiaris N., Mazarakis N.D., Mintz P.J., Hajitou A. Dual systemic tumor targeting with ligand-directed phage and Grp78 promoter induces tumor regression. Mol. Cancer Ther. 2012, 11:2566-2577.
166. Haviv Y.S., van Houdt W.J., Lu B., Curiel D.T., Zhu Z.B. Transcriptional targeting in renal cancer cell lines via the human CXCR4 promoter. Mol. Cancer Ther. 2004, 3:687-691.
167. Zhu Z.B., Makhija S.K., Lu B., Wang M., Kaliberova L., Liu B., Rivera A.A., Nettelbeck D.M., Mahasreshti P.J., Leath C.A., Yamamoto M., Alvarez R.D., Curiel D.T. Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter. Gene Ther. 2004, 11:645-648.
168. Rajendran S., O'Sullivan G.C., O'Hanlon D., Tangney M. Adenovirus-mediated transcriptional targeting of colorectal cancer and effects on treatment-resistant hypoxic cells. Clin. Colorectal Cancer 2013, 12:152-162. (e151).
169. Balani P., Boulaire J., Zhao Y., Zeng J., Lin J., Wang S. High mobility group box2 promoter-controlled suicide gene expression enables targeted glioblastoma treatment. Mol. Ther. 2009, 17:1003-1011.
170. Akerstrom V., Chen C., Lan M.S., Breslin M.B. Adenoviral insulinoma-associated protein 1 promoter-driven suicide gene therapy with enhanced selectivity for treatment of neuroendocrine cancers. Ochsner J. 2013, 13:91-99.
171. Tsuruta Y., Pereboeva L., Breidenbach M., Rein D.T., Wang M., Alvarez R.D., Siegal G.P., Dent P., Fisher P.B., Curiel D.T. A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Clin. Cancer Res. 2008, 14:3582-3588.
172. Hine C.M., Seluanov A., Gorbunova V. Rad51 promoter-targeted gene therapy is effective for in vivo visualization and treatment of cancer. Mol. Ther. 2012, 20:347-355.
173. Hine C.M., Seluanov A., Gorbunova V. Use of the Rad51 promoter for targeted anti-cancer therapy. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:20810-20815.
174. Fontecedro A.C., Lutschg V., Eichhoff O., Dummer R., Greber U.F., Hemmi S. Analysis of adenovirus trans-complementation-mediated gene expression controlled by melanoma-specific TETP promoter in vitro. Virol. J. 2010, 7:175.